Extranodal NK/T-cell lymphoma presenting with primary cardiac involvement

Lisa M. Lepeak,1 David T. Yang,2 Julie E. Chang1

1Section of Hematology and Oncology, University of Wisconsin Carbone Cancer Center, Madison, WI; 2Section of Pathology and Laboratory Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI, USA

Abstract

Primary cardiac lymphoma is extremely uncommon. We report a case of a 54 year old Caucasian male with a history of non-small cell lung cancer treated by surgical resection who presented with chest pain and dyspnea on exertion. Computerized tomography (CT) imaging confirmed a 7.8x3.8 cm right atrial soft tissue mass infiltrating the lateral wall of the right atrium, and a 5 cm pericardiophrenic mass. Echocardiography confirmed a moderate pericardial effusion without tamponade physiology. Percutaneous biopsy of the pericardiophrenic mass revealed pathologic features diagnostic of NK/T-cell lymphoma. He received CHOP chemotherapy with some improvement in symptoms, but experienced radiographic progression after 2 cycles. He received palliative involved field radiotherapy but developed new sites of progressive disease within the abdomen and died shortly after completing radiotherapy. NK/T-cell lymphomas are aggressive tumors that may present with unusual extranodal disease sites. Prompt diagnosis with consideration for referral to a specialty center with experience in treatment of these rare tumors may offer the greatest potential for improving treatment outcomes.

Introduction

NK/T-cell lymphomas (NKTCls) represent an uncommon subtype of non-Hodgkin's lymphoma (NHL), comprising only 5% of NHL cases in Western countries.1,2 NKTCls are highly aggressive, accounting for their previous description as lethal midline granulomas. NKTCls generally have poor outcomes, with high rates of relapse and progression even in the setting of limited stage disease.1,3 At least 80% of NKTCls are localized at presentation, most commonly to the nasal cavity with extension to the nasopharynx and paranasal sinuses.3 However, distant sites of involvement may be observed, most commonly involving the skin, liver, lung, gastrointestinal tract, or testis.1 In cases of extranodal NKTCls, only rare reports exist of primary cardiac involvement.1-4 We report a rare case of a patient with extranodal NKTL presenting with primary cardiac involvement.

Case Report

A 54 year old Caucasian male with a history of polysubstance abuse and stage IA squamous cell lung carcinoma resected 2 years previously, presented to clinic with a 3 month history of progressive chest pain and dyspnea on exertion. Physical examination revealed normal vital signs and no abnormalities on cardiopulmonary examination. Chest x-ray revealed a new mass in the anterior left lower mediastinum. Computerized tomography (CT) imaging of the chest showed a 7.8x3.8 cm right atrial soft tissue mass infiltrating the lateral wall of the right atrium, and a 5 cm pericardiophrenic mass. Echocardiography confirmed a moderate pericardial effusion without tamponade physiology. A percutaneous core needle biopsy of the pericardiophrenic mass was performed (Figure 2). Hematoxylin and eosin stained sections of the mediastinal mass revealed a dense infiltrate of primarily small lymphocytes with irregular nuclear contours in a background of focal fibrosis and scattered histiocytes. Immunohistochemistry and in situ hybridization demonstrated that the neoplastic cells co-expressed CD3ε, CDS6, Epstein-Barr virus encoded RNA, granzyme-B, and TIA-1. Mitotic figures were easily found, but angiodestruction was not present. The final pathologic diagnosis was extranodal NK/T-cell lymphoma, nasal-type.

A unilateral bone marrow biopsy did not show any morphologic evidence of involvement by lymphoma. Flow cytometry on the bone marrow biopsy was negative and immunostaining for EBER was negative. Retrospective review of his non-small cell lung cancer biopsy confirmed squamous carcinoma with no atypical findings, and EBER immunostaining was negative. His blood counts at diagnosis were normal, including a normal LDH of 160 U/L. HIV testing was negative. Nasal endoscopy with biopsies and CT/PET imaging were recommended in order to complete the staging evaluation. Multiple attempts were made to schedule and perform these procedures, but the patient was unwilling and/or unable to comply due to his chaotic psychosocial circumstances and his concerns about costs due to lack of medical insurance.

Although a more dose-intensive regimen would have been preferred, CHOP chemotherapy was administered for palliative treatment in this case due to issues with poor patient compliance and continued polysubstance abuse. Two attempts had been made to administer the more dose-intensive SMILE (steroids, methotrexate, ifosfamide, L-asparaginase, and etoposide) regimen as an inpatient, but the patient left within several hours of admission against medical advice. There were several intervening emergency department visits with tachyarrhythmias and cocaine intoxication. Based on these limiting factors, the patient received 2 cycles of CHOP chemotherapy.

Figure 1. Computerized tomography imaging confirms a large left pericardiac mass (top right arrow) and infiltrative mass arising from the right atrium (left arrow).
Involvement of aggressive lymphoma subtypes presenting with advanced stage disease and extranodal are extrapolated from experience with other clinical management decisions of this entity. Chemotherapy resistance (MDR1 gene). High-intensive protein, which is the product of the multidrug resistance (MDR1) gene.

The rarity of primary cardiac lymphomas, most clinical management decisions of this entity are extrapolated from experience with other aggressive lymphoma subtypes presenting with advanced stage disease and extranodal involvement.

Chemotherapy resistance of NKTLs may be related to high rates of expression of P-glycoprotein, which is the product of the multidrug resistance (MDR) 1 gene. High-intensive chemotherapy regimens combined with radiotherapy may be a rationale means for bypassing the innate MDR of NKTLs, with some limited data to support improved outcomes with such an approach. L-asparaginase has shown impressive single-agent activity in NKTLs. More recent reports have focused on combining L-asparaginase with chemotherapy agents known to be independent of MDR. For example, outcomes with the SMILE regimen, have reported rates of response exceeding 50% in a phase I study of relapsed, refractory NKTLs. These promising results have led to on ongoing phase II study of SMILE chemotherapy in Asia.

Although prognosis remains poor in disseminated NKTLs, prompt diagnosis and possible referral to a specialty center with experience in treatment of NKTLs may offer patients the best opportunity for longer-term disease outcomes.

**Discussion**

Although improved outcomes have been reported with combined chemoradiation for treatment of limited stage nasal NK/T-cell lymphoma, outcomes remain poor for disseminated disease and extranasal NKTLs. Given the rarity of primary cardiac lymphomas, most clinical management decisions of this entity are extrapolated from experience with other aggressive lymphoma subtypes presenting with advanced stage disease and extranodal involvement.

Chemotherapy resistance of NKTLs may be related to high rates of expression of P-glycoprotein, which is the product of the multidrug resistance (MDR) 1 gene. High-intensive chemotherapy regimens combined with radiotherapy may be a rationale means for bypassing the innate MDR of NKTLs, with some limited data to support improved outcomes with such an approach. L-asparaginase has shown impressive single-agent activity in NKTLs. More recent reports have focused on combining L-asparaginase with chemotherapy agents known to be independent of MDR. For example, outcomes with the SMILE regimen, have reported rates of response exceeding 50% in a phase I study of relapsed, refractory NKTLs. These promising results have led to on ongoing phase II study of SMILE chemotherapy in Asia.

Although prognosis remains poor in disseminated NKTLs, prompt diagnosis and possible referral to a specialty center with experience in treatment of NKTLs may offer patients the best opportunity for longer-term disease outcomes.

**References**

1. Kohr H, Advani R. Extranodal natural killer/T-cell lymphoma: Current concepts in biology and treatment. Leuk Lymphoma 2009;50:1773-84.
2. Au WY, Weisenburger DD, Intragumtochai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: A study of 136 cases from the international peripheral T-cell lymphoma project. Blood 2009;113:3931-7.
3. Cheung MM, Chan JK, Wong KF. Natural killer cell neoplasms: A distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol 2003;40:221-32.
4. Fernandes F, Soufen HN, Ianni BM, Arteaga E, Ramires FJ, Mady C: Primary neoplasms of the heart. Clinical and histological presentation of 50 cases. Arch Bras Cardiol 2001;76:231-7.
5. Lam KY, Dickens P, Chan AC. Tumors of the heart. A 20-year experience with a review of 12,485 consecutive autopsies. Arch Pathol Lab Med 1993;117:1027-31.
6. Bagwan IN, Desai S, Wotherspoon A, Sheppard MN. Unusual presentation of primary cardiac lymphoma. Interact Cardiovasc Thorac Surg 2009;9:127-9.
7. Kim SJ, Kim K, Kim BS, et al. Phase ii trial of concurrent radiation and weekly cisplatin followed by vidp chemotherapy in newly diagnosed, stage ie to iie, nasal, extranodal nk/T-cell lymphoma: Consortium for improving survival of lymphoma study. J Clin Oncol 2009;27:6027-32.
8. Yamaguchi M, Tobiina K, Oguchi M, et al. Phase i/ii study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan clinical oncology group study jcog0211. J Clin Oncol 2009;27:5594-600.
9. Anghel G, Zoli V, Petti N, et al. Primary cardiac lymphoma: Report of two cases occurring in immunocompetent subjects. Leuk Lymphoma 2004;45:781-8.
10. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of p-glycoprotein/mdr1 by nasal t-cell lymphoma cells. Cancer 1995;76:2351-6.
11. Aviles A, Cleto S, Castaneda C, Nambo MJ. Cned in the treatment of nasal natural killer cell lymphoma with distant metastases. Hematology 2007;12:241-4.
12. Jaccard A, Petit B, Girault S, et al. L-asparaginase-based treatment of 15 western patients with extranodal nk/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 2009;20:110-6.
13. Yamaguchi M, Suzuki R, Kwong YL, et al. Phase i study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (smile) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (nk/T)-cell lymphoma and leukemia. Cancer Sci 2008;99:1016-20.